Private company

Essa Pharma (United States)

Essa Pharma (United States) is an American pharmaceutical preparations company based in Houston, founded in 2009.1

Last updated Oct 20, 2026.

Overview

-$28.5MNet income, fiscal 20243
2009Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston1
  • Websiteessapharma.com
  • Incorporated inBritish Columbia, Canada4
  • Business addressSuite 720, 999 West Broadway, Vancouver4
  • Filer categoryNon-accelerated filer, Smaller reporting company4

See how the biggest companies compare on our leaderboards

ESSA is a clinical stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer with a primary focus on patients whose disease is still predominantly driven by the androgen axis. ESSA’s development of proprietary small molecule inhibitors of the N-terminal domain (“NTD”) of the androgen receptor (“AR”) was focused on the treatment of these patients in combination with second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-22.9%Return on equity3

Financial statements

Net income789103-$28.5M in 2024+534% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$4.5M-$4.5M20172018: -$11.6M-$11.6M2018+158%2019: -$12.8M-$12.8M2019+10%2020: -$23.4M-$23.4M2020+84%2021: -$36.8M-$36.8M2021+57%2022: -$35.1M-$35.1M2022−5%2023: -$26.6M-$26.6M2023−24%2024: -$28.5M-$28.5M2024+7%
Fiscal year20172018201920202021202220232024
Research and development$6.7M8$12.1M8$24.3M9$24.4M10$21.3M3$21.2M3
Operating expenses$37.0M10$32.1M3$34.4M3
Income before tax-$35.2M10-$26.6M3-$28.5M3
Income tax$37.9K8-$288.6K8-$34.3K9-$111.8K10$1.6K3
Net income-$4.5M7-$11.6M7-$12.8M8-$23.4M8-$36.8M9-$35.1M10-$26.6M3-$28.5M3
Earnings per share-$0.969-$0.8010-$0.603-$0.643
Earnings per share (diluted)-$0.969-$0.8010-$0.603-$0.643
Shares (weighted, basic)44.0M shares1044.1M shares344.3M shares3
Shares (weighted, diluted)44.0M shares1044.1M shares344.3M shares3

Compare Essa Pharma (United States) with another company

Corporate structure

Essa Pharma (United States) sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Essa Pharma (United States)

  • TANG CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Essa Pharma (United States), latest Nov 14, 2025 (4 filings since Nov 8, 2024)
  • BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13D/A on Essa Pharma (United States), latest Oct 14, 2025 (5 filings since Feb 14, 2022)
  • Morgan Stanley Filed SCHEDULE 13G/A on Essa Pharma (United States), latest Oct 7, 2025 (2 filings since Feb 8, 2024)
  • Soleus Capital Master Fund, L.P. Filed SCHEDULE 13D/A on Essa Pharma (United States), latest Jul 21, 2025 (3 filings since Apr 15, 2025)
  • BML Investment Partners, L.P. Filed SCHEDULE 13D on Essa Pharma (United States), latest Apr 24, 2025 (4 filings since Nov 7, 2024)
  • PFM Health Sciences, LP Filed SCHEDULE 13G/A on Essa Pharma (United States), latest Feb 14, 2025 (5 filings since Nov 10, 2022)
  • RTW INVESTMENTS, LP Filed SCHEDULE 13G/A on Essa Pharma (United States), latest Feb 14, 2025 (5 filings since Feb 14, 2022)
  • Soleus Capital, LLC Filed SCHEDULE 13G/A on Essa Pharma (United States), latest Feb 11, 2025 (4 filings since Feb 10, 2022)
  • BB Biotech Filed SC 13G/A on Essa Pharma (United States), latest Nov 14, 2024 (4 filings since Feb 11, 2022)
  • Avidity Partners Management LP Filed SC 13G/A on Essa Pharma (United States), latest Feb 14, 2023 (2 filings since Oct 27, 2022)
  • EVENTIDE ASSET MANAGEMENT, LLC Filed SC 13G/A on Essa Pharma (United States), latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Janus Henderson Group Ltd. Filed SC 13G/A on Essa Pharma (United States), latest Feb 9, 2023 (2 filings since Feb 11, 2022)
  • Essa Pharma (United States) Houston
    • State of Subsidiary · Texas, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Essa Pharma (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$295.5K3 Sep 30, 2024$68.0K3 Sep 30, 2023+334.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$103.7M3 Sep 30, 2024$33.7M3 Sep 30, 2023+207.7%
Marketable securities, current$23.1M3 Sep 30, 2024$114.4M3 Sep 30, 2023−79.8%
Debt securities available for sale$114.4M10 Sep 30, 2023$110.2M10 Sep 30, 2022+3.8%

Properties, in its own words

Our headquarters are located in Vancouver, British Columbia, where we rent office space on a short-term lease. Our U.S. offices are located in South San Francisco, California. In March 2018, we entered into a lease for the South San Francisco office that expired on March 31, 2021, and which we have extended to July 31, 2027.

We believe that our existing facilities are adequate for our immediate needs and can accommodate our anticipated growth. We believe that, should it be needed, additional space can be leased to accommodate any future growth.

Item 2 of the 10-K filed Dec 17, 2024.6

Leadership

Who has led Essa Pharma (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Ross Parkinson2020–now

President

  1. David Ross Parkinson2025–now

Chief operating officer

  1. Peter Virsik2020–now
2010201520202025
Board members and other officers (11)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • State of Texas5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 9, 20258-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights28
  2. Oct 6, 20258-K Shareholder vote; Other events29
  3. Oct 3, 20258-K Other events30
  4. Sep 30, 20258-K Other events31
  5. Sep 24, 20258-K Entered a material agreement; Other events32
  6. Sep 10, 20258-K Other events33
  7. Aug 25, 20258-K Other events34
  8. Aug 14, 20258-K Other events35
  9. Aug 6, 20258-K Other events36
  10. Jul 31, 20258-K Other events37
  11. Jul 23, 20258-K Other events38
  12. Jul 14, 20258-K Entered a material agreement; Other events39
  13. Oct 1, 2020New chief executive David Ross Parkinson becomes CEO15
  14. 2009Founded Founded1

Calendar

When it reported results

  1. May 8, 2025Reported quarterly or annual results40
  2. Feb 11, 2025Reported quarterly or annual results41
  3. Dec 17, 2024Reported quarterly or annual results42
  4. Aug 5, 2024Reported quarterly or annual results43
  5. May 14, 2024Reported quarterly or annual results44
  6. Feb 13, 2024Reported quarterly or annual results45
  7. Dec 12, 2023Reported quarterly or annual results46
  8. Aug 8, 2023Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

210 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 45 major events, 61 insider forms, 45 large holders, 43 other. The latest 20:

  1. Nov 14, 2025EFFECT EDGAR
  2. Nov 14, 2025SCHEDULE 13G/A EDGAR
  3. Nov 14, 2025SCHEDULE 13G/A EDGAR
  4. Oct 28, 202515-12G EDGAR
  5. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  6. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  7. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  8. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  9. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  10. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  11. Oct 15, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Oct 15, 2025POS AM EDGAR
  13. Oct 15, 2025S-8 POS EDGAR
  14. Oct 15, 2025S-8 POS EDGAR
  15. Oct 15, 2025S-8 POS EDGAR
  16. Oct 15, 2025S-8 POS EDGAR
  17. Oct 15, 2025S-8 POS EDGAR
  18. Oct 14, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Oct 14, 2025SCHEDULE 13D/A EDGAR
  20. Oct 9, 20258-K EDGAR

The 210 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 13 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 5, 2025BVF INC/IL10% ownerSale156$1.88$293Form 4
Nov 1, 2024BB BIOTECH AG10% ownerSale7,879,583$1.53$12.0MForm 4
Oct 7, 2024Virsik PeterChief Operating OfficerSale694$6.03$4.2KForm 4
Sep 9, 2024Virsik PeterChief Operating OfficerSale694$6.00$4.2KForm 4
Sep 3, 2024Virsik PeterChief Operating OfficerSale2,082$6.03$12.6KForm 4
May 6, 2024Virsik PeterChief Operating OfficerSale694$6.95$4.8KForm 4
Apr 5, 2024Virsik PeterChief Operating OfficerSale694$7.94$5.5KForm 4
Mar 5, 2024Virsik PeterChief Operating OfficerSale694$8.98$6.2KForm 4
Feb 6, 2024Virsik PeterChief Operating OfficerSale72,782$10.29$748.9KForm 4
Feb 5, 2024Virsik PeterChief Operating OfficerSale1,194$9.58$11.4KForm 4
Jan 16, 2024Virsik PeterChief Operating OfficerSale1,718$10.01$17.2KForm 4
Jan 5, 2024Virsik PeterChief Operating OfficerSale699$6.11$4.3KForm 4
Dec 14, 2023Parkinson David RossPresident and CEOBuy9,223$2.30$21.2KForm 4
Nov 21, 2023BERGER FRANKLIN MDirectorBuy23,259$5.73$133.3KForm 4
Nov 3, 2023BERGER FRANKLIN MDirectorBuy16,471$5.99$98.7KForm 4
Nov 2, 2023BERGER FRANKLIN MDirectorBuy60,000$5.35$321.0KForm 4
Dec 30, 2022Parkinson David RossPresident and CEOBuy3,067$2.60$8.0KForm 4
Dec 30, 2022Wood David S.Chief Financial OfficerBuy8,302$2.60$21.6KForm 4
Dec 22, 2022Parkinson David RossPresident and CEOBuy21,367$2.39$51.1KForm 4
Dec 21, 2022BERGER FRANKLIN MDirectorSale72,223$2.41$174.4KForm 4

All 31 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024David R. Parkinson$601.9K$4.1M63
2024Alessandra Cesano$488.6K$2.5M63
2024Peter Virsik$494.0K$1.7M63
2024David Wood$451.4K$1.7M63
2023Chief Executive Officer and President$577.6K$813.9K63
2023Executive VicePresident and Chief Operating Officer$473.9K$646.0K63
2023Chief Financial Officer$428.2K$590.4K63

SEC filer profile

How Essa Pharma (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARESSA Pharma Inc.2
  • CIK0001633932
  • Employer ID (EIN)98-12507036
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
  • Incorporated inBritish Columbia6
  • Fiscal year endsSeptember 302
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressSuite 720, 999 West Broadway, Vancouver, British Columbia, Canada2
  • Phone(778) 331-09622
  • Shares outstanding47,308,394 as of Aug 13, 202512
  • Public float$376.6M as of Mar 31, 20246
  • AuditorDAVIDSON & COMPANY LLP, Vancouver, Canada PCAOB ID 731; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceFeb 24, 20152
  • Filings513 in all: 6-K (132), 4 (72), 8-K (52), SC 13G/A (44), SC 13G (21), 3 (17), 10-Q (15), DEFA14A (15)2
    All 48 form types

    CORRESP (13), UPLOAD (11), 4/A (8), EFFECT (8), SC 13D (8), SCHEDULE 13G/A (8), SC 13D/A (7), 424B5 (6), S-8 (6), S-8 POS (6), 10-K (5), 20-F (5), DEF 14A (5), 144 (4), SCHEDULE 13D/A (4), D (3), F-3 (3), S-3 (3), S-3/A (3), SCHEDULE 13D (3), SUPPL (3), 20FR12B/A (2), DRS/A (2), DRSLTR (2), F-3/A (2), 15-12G (1), 20FR12B (1), 25-NSE (1), CERTNAS (1), CT ORDER (1), DEFM14A (1), DRS (1), F-10 (1), F-10/A (1), F-X (1), POS AM (1), PRE 14A (1), PREM14A (1), S-3ASR (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Dec 17, 2024
    Quarterly report (10-Q) Aug 13, 2025
    Proxy statement (DEF 14A) Jan 22, 2025
    Latest 8-K (8-K) Oct 9, 2025

Securities registered for trading

ClassSymbolExchange
Common SharesEPIXNasdaq

From the cover page of the 10-K filed Dec 17, 2024 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks Essa Pharma (United States) names in Item 1A of its 10-K filed Dec 17, 2024: 48 risks under these headings, as written.6

  • Regulatory Matters
  • ESSA may not be successful in its efforts to build out a pipeline of product candidates.
  • Failure to comply with applicable legal and regulatory requirements may result in administrative or judicial sanctions.
  • Risks Related to ESSA’s Financial Position and Need for Additional Capital
  • ESSA will have significant additional future capital needs and there are uncertainties as to the Company’s ability to raise additional funding.
  • ESSA may not be able to raise additional capital on favorable terms, which may result in dilution to ESSA’s existing shareholders, restrictions on ESSA’s operations or the requirement for ESSA to relinquish rights to technologies.
  • The Company was subject to the restrictions and conditions of the CPRIT Agreement for a period of time after receipt of the last grant payment. Failure to have complied with the CPRIT Agreement may materially and adversely affect ESSA’s financial condition.
  • The Company has incurred significant losses in every quarter since its inception and anticipates that it will continue to incur significant losses in the future and may never generate profits from operations or achieve profitability.
  • ESSA has a limited operating history, which may make it difficult for you to evaluate the success of ESSA’s business to date and to assess ESSA’s future viability.
  • Risks Related to ESSA’s Intellectual Property
  • ESSA relies on proprietary technology, the protection of which can be unpredictable and costly.
  • ESSA may not be able to protect its intellectual property rights throughout the world.
The other 39 risks
  • Obtaining and maintaining ESSA’s patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and ESSA’s patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If ESSA does not obtain protection under the Hatch-Waxman Amendments and similar legislation in other countries for extending the term of patents covering each of its product candidates, ESSA’s business may be materially harmed.
  • Confidentiality Agreements with employees and third parties may not prevent unauthorized disclosure of Company proprietary information, which would harm ESSA’s competitive position.
  • If ESSA’s trademarks and trade names are not adequately protected, the Company may not be able to build name recognition in its markets of interest and its business, financial condition, results of operations and prospects could be significantly harmed.
  • Intellectual property litigation may lead to unfavorable publicity that harms ESSA’s reputation and causes the market price of the Common Shares to decline.
  • ESSA’s intellectual property rights may not necessarily provide the Company with competitive advantages and its patent terms may be inadequate to protect the Company’s competitive position on its product candidates for an adequate amount of time.
  • Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing ESSA’s ability to protect its planned products.
  • Risks Related to ESSA’s Business and Industry
  • ESSA may not be successful in identifying and implementing any strategic transaction and any strategic transaction that it may consummate in the future may not be successful.
  • ESSA may not realize any additional value in a strategic transaction.
  • If ESSA is successful in completing a strategic transaction, it may be exposed to other operational and financial risks.
  • ESSA’s decision to discontinue development of masofaniten and any related reduction in its workforce may not result in any anticipated savings and could disrupt ESSA’s business.
  • ESSA may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to shareholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be distributed for outstanding liabilities.
  • ESSA’s ability to consummate a strategic transaction depends on its ability to retain its employees required to consummate such transaction.
  • ESSA may become involved in securities class action litigation that could divert management’s attention and harm ESSA’s business, and insurance coverage may not be sufficient to cover all costs and damages.
  • ESSA and its collaborators are subject to evolving global laws and regulations relating to privacy, data protection and information security, which may require them to incur substantial compliance costs, and any failure or perceived failure by ESSA and its collaborators to comply with such laws and regulations may harm ESSA’s business and operations.
  • ESSA’s business and operations could suffer in the event of an actual or perceived information security incident such as a cybersecurity breach, system failure, or other compromise of its systems and/or information, including information held by a third-party contractor or vendor.
  • Business disruptions could seriously harm ESSA’s future revenues and financial condition and increase costs and expenses.
  • The directors and officers of ESSA may be subject to conflicts of interest.
  • The Company may face exposure to adverse movements in foreign currency exchange rates.
  • The Company may acquire businesses or products or form strategic alliances in the future and the Company may not realize the benefits of such acquisitions.
  • ESSA’s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for ESSA and harm ESSA’s reputation.
  • If product liability lawsuits are brought against the Company or its strategic partners, it may incur substantial liabilities and may be required to cease or limit the sale, marketing and distribution of its product candidate and potential future products.
  • ESSA incurs significantly increased costs and devotes substantial management time as a result of operating as a public company.
  • ESSA is a smaller reporting company and a non-accelerated filer, and the reduced disclosure requirements available to ESSA may make ESSA’s Common Shares less attractive to investors.
  • Risks Related to Additional Legal Compliance and Regulatory Matters
  • ESSA is subject to risks inherent in foreign operations.
  • If ESSA fails to comply with environmental, health and safety laws and regulations, ESSA could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of ESSA’s business.
  • ESSA is and there is a risk that ESSA may continue to be a “passive foreign investment company” which would likely result in materially adverse U.S. federal income tax consequences for U.S. investors.
  • It may be difficult for United States investors to effect services of process or enforcement of actions against the Company or certain of its directors and officers under U.S. federal securities laws.
  • Risks Relating to ESSA’s Common Shares
  • The market price and trading volume of ESSA’s Common Shares may be volatile, which could result in rapid and substantial losses for its shareholders or securities litigation.
  • ESSA is at risk of securities class action litigation.
  • ESSA’s management has broad discretion over the use of its cash and may not use our cash effectively, which could adversely affect ESSA’s results of operations.
  • The Company has never declared dividends and may not do so in the future.
  • The Company may experience future sales or issue additional securities.
  • An active trading market for the Common Shares may not be sustained.
  • General Risk Factors
  • Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.
  • Widespread health concerns, pandemics or epidemics, and other outbreaks of illness may negatively affect the Company’s ability to maintain operations and execute its business plan.
  • If ESSA is unable to implement and maintain effective internal control over financial reporting in the future, ESSA may not be able to report financial results accurately or prevent fraud. In that case, investors may lose confidence in the accuracy and completeness of ESSA’s financial reports and the market price of ESSA’s Common Shares may be negatively affected.
  • Provisions in ESSA's corporate charter documents and Canadian law could make an acquisition of the Company, which may be beneficial to ESSA's shareholders, more difficult and may prevent attempts by the shareholders to replace or remove ESSA's current management and/or limit the market price of the Common Shares.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about ESSA’s business, its stock price and trading volume could decline.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of September 30, 2024, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
    SEC EDGAROther events
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63